Targeting this group of TAMs with a Mer tyrosine kinase inhibitor can block their efferocytosis function, enhance the activity of CD8+ T cells, restore antitumor immune function in PDAC liver metastasis, and prevent tumor metastasis and growth [57]. Here, CD8A is linked to neoplasm.